A phase II study of sapanisertib (TAK-228) a mTORC1/2 inhibitor in rapalog-resistant advanced pancreatic neuroendocrine tumors (PNET): ECOG-ACRIN EA2161.
Saved in:
| Title: | A phase II study of sapanisertib (TAK-228) a mTORC1/2 inhibitor in rapalog-resistant advanced pancreatic neuroendocrine tumors (PNET): ECOG-ACRIN EA2161. |
|---|---|
| Authors: | Rajdev L; Zucker School of Medicine at Hofstra, Hempstead, NY, USA. lrajdev2@gmail.com., Lee JW; Dana Farber Cancer Institute - ECOG-ACRIN Biostatistics Center, Boston, MA, USA., Libutti SK; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA., Benson AB; Northwestern University, Evanston, IL, USA., Fisher GA Jr; Stanford University, Stanford, CA, USA., Kunz PL; Yale School of Medicine, New Haven, CT, USA., Hendifar AE; Cedars-Sinai Medical Center, Los Angeles, CA, USA., Catalano P; Dana Farber Cancer Institute - ECOG-ACRIN Biostatistics Center, Boston, MA, USA., O'Dwyer PJ; University of Pennsylvania/Abramson Cancer Center, Philadelphia, PA, USA. |
| Source: | Investigational new drugs [Invest New Drugs] 2022 Dec; Vol. 40 (6), pp. 1306-1314. Date of Electronic Publication: 2022 Oct 20. |
| Publication Type: | Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural |
| Journal Info: | Publisher: Springer Country of Publication: United States NLM ID: 8309330 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1573-0646 (Electronic) Linking ISSN: 01676997 NLM ISO Abbreviation: Invest New Drugs Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
